Discover why MDGL's Rezdiffra leads in MASH therapy with rapid US and EU expansion. Learn about growth potential and risks.

In recent weeks Novo Nordisk has secured several key label expansions for some of its products, which should contribute ...

While only two therapies have so far gained approval, the broader pipeline paints a picture of strong research and ...

Small and large drugmakers alike have made big, proactive moves to secure the production capacity that will be vital to ...

The week's pharma news includes FDA warnings for Lilly and Novo, new drug approvals for MASH and edema, and a look ahead at ...

The $14.50-per-share deal equates to a purchase price of $2.4 billion at closing, with Roche dangling another $6 per share in ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...